July 16, 2019
Japan Tobacco’s HIF-PH inhibitor enarodustat showed non-inferiority versus the erythropoiesis-stimulating agent (ESA) Nesp (darbepoetin alfa) for the treatment of renal anemia in both non-dialysis and hemodialysis patients with chronic kidney disease. JT and its subsidiary Torii Pharmaceutical said on July...read more